Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02438917 · ClinicalTrials.gov registry record

Biomarkers of Liver Fibrosis

A clinical trial, sponsored by Icahn School of Medicine at Mount Sinai.

Terminated
Registry status
10
Enrollment target

NCT02438917 is a clinical trial that was terminated before completion, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 10 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02438917 was terminated before completion, sponsored by Icahn School of Medicine at Mount Sinai.

TERMINATED
Registry status
10 participants
Enrollment target

Study Summary

Chronic liver injury leads to the accumulation of proteins in the liver that form dense scars. Liver scar formation is typically a slow process that leads to major organ damage and loss of function over the course of many years. During scar formation the extracellular matrix in the liver changes. The type and quantity of extracellular collagen and other proteins change during tissue remodeling. Some of these changes can be detected by analyzing factors present in blood. Because of the lengthy time course, changes in the rate of liver scar formation and regression are very difficult measure; however, accurate measurements are needed in order to conduct trials of interventions aimed at preventing scar formation and/or promotion scar regression. Current methods have sub-optimal specificity and selectivity. The long term objective of the study is to identify serum proteins that can be used to accurately estimate rates of liver fibrosis progression and regression. The project focusses on a novel methodology that uses stable isotope labeling with deuterated water, D2O, to tag newly-synthesized proteins. Mass spectroscopy is used to identify individual proteins and to quantify the ratio of labeled protein to total protein. This ratio provides information about the rate of synthesis of the protein of interest. This method will be applied to specimens from patients with hepatitis C virus (HCV) infection who are about to begin HCV treatment. Treatment is known to reduce liver inflammation and collagen content.

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2015-06
Est. Completion 2017-03-03

What the Registry Record Tells You About NCT02438917

The ClinicalTrials.gov registry entry for NCT02438917 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT02438917 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02438917 about?

NCT02438917 is a clinical study titled "Biomarkers of Liver Fibrosis". Chronic liver injury leads to the accumulation of proteins in the liver that form dense scars. Liver scar formation is typically a slow process that leads to major organ damage and loss of function over the course of many years. During scar formation the extracellular matrix in the liver changes. Th...

What is the current status of trial NCT02438917?

This trial is currently terminated. The enrollment target is 10 participants. The study started on 2015-06. Estimated completion is 2017-03-03.

Who is sponsoring clinical trial NCT02438917?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.